GLP-1 Medications May Reduce Breast Cancer Risk, Penn Medicine Study Finds

A recent study conducted by researchers at Philadelphia-based Penn Medicine indicates a potential link between the use of GLP-1 medications and a reduced risk of breast cancer. The findings suggest that women who were prescribed GLP-1 drugs were approximately 30% less likely to develop breast cancer compared to those who did not use these medications. This research opens new discussions on the potential broader health benefits of GLP-1s, beyond their established roles in managing diabetes and obesity.

The observational study, published in JCO Oncology Practice, analyzed health records of nearly 112,000 women between the ages of 45 and 80, all with a BMI of 25 or higher. The data, collected from January 2022 to June 2025, revealed a significant association. Among the participants, 15,264 had GLP-1 prescriptions, while 96,382 did not. Researchers found that women taking GLP-1 medications had a 35.1% lower risk of developing breast cancer. This association remained even after accounting for factors like age, race, ethnicity, body mass index, breast density, and diabetes status.

Key Takeaways from the Study

The study, led by Elizabeth McDonald, MD, PhD, a professor of Radiology at the Hospital of the University of Pennsylvania, highlights that while the findings show a strong association, they do not definitively prove that GLP-1s prevent breast cancer. However, the significance of the link warrants further robust clinical trials to understand the underlying biological mechanisms. Experts suggest that the weight loss and metabolic improvements associated with GLP-1 use could be contributing factors to this observed reduction in cancer risk, as obesity is a known risk factor for breast cancer.

Implications for Indian Healthcare and Research

For India, where breast cancer is a growing concern and the prevalence of obesity and type 2 diabetes is also rising, these findings could have significant implications. If future research confirms a causal link, GLP-1 medications could become a valuable tool in breast cancer prevention strategies, particularly for at-risk populations. Indian medical researchers and pharmaceutical companies may look to explore these avenues further, potentially leading to local studies and clinical trials adapted to the Indian context.

The potential for GLP-1 drugs to offer benefits beyond their primary indications is a rapidly evolving area of medical research. Earlier studies have already pointed towards GLP-1 users being less prone to the spread of certain obesity-related cancers. The current study adds breast cancer to the list of potential health conditions that these medications might influence positively.

Understanding GLP-1 Medications

GLP-1 receptor agonists are a class of medications primarily used for the treatment of type 2 diabetes and obesity. They work by mimicking the action of glucagon-like peptide-1, a hormone that helps regulate blood sugar levels, reduce appetite, and promote feelings of fullness. Popular examples include Ozempic, Wegovy, and Zepbound. While these drugs have gained prominence for their weight loss effects, their potential impact on cancer risk adds another dimension to their therapeutic profile.

Expert Perspectives

Gilberto Lopes, MD, chief of the division of Medical Oncology with Sylvester Comprehensive Cancer Center, part of the University of Miami Health System, noted the importance of this new research. Amy Bremner, MD, a Breast Surgical Oncologist, emphasized that if GLP-1 drugs indeed help lower the risk of breast cancer, the benefits for women's health would be transformative. The medical community acknowledges that while observational studies like this are crucial for identifying potential associations, they serve as a call for more rigorous, controlled trials to establish causation and explore mechanisms.

Key facts:
| Aspect | Detail |
|—|—|
| Researchers | Penn Medicine, Philadelphia |
| Key Finding | GLP-1 users 30-35% less likely to develop breast cancer |
| Study Population | ~112,000 women, ages 45-80, BMI ≥ 25 |
| Publication | JCO Oncology Practice |

The study's findings are particularly relevant for Indian healthcare professionals and policymakers. As India grapples with the dual burden of non-communicable diseases, including cancer and metabolic disorders, understanding the broader impact of existing medications can inform public health strategies. For Indian teams in digital health, pharma marketing, or health tech startups, this research highlights a growing area of interest and potential for patient education and support services around GLP-1 medications. It also underscores the importance of data-driven research in identifying novel applications for existing treatments.

Source: Beckershospitalreview.com, https://www.beckershospitalreview.com/glp-1s/glp-1-use-linked-to-lower-breast-cancer-risk-study/

Key facts

Point	Detail
Source	beckershospitalreview.com
Date	2026-06-02T14:45:56+00:00
Topic	GLP-1 use linked to lower breast cancer risk: Study